Morgan Stanley maintains BridgeBio Pharma at Overweight, raises price target to $91 from $88

Morgan Stanley kept its Overweight rating on BridgeBio Pharma and increased its price target to $91 from $88, suggesting a 16.4% upside from the Nov 12 close of $78.17. Recent analyst price targets for the company range from $88 to $120.

Original reporting
Published Nov 13, 2026, 5:53 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 13, 2026, 6:02 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Morgan Stanley maintains BridgeBio Pharma at Overweight, raises price target to $91 from $88 — source image
Decision brief

The 30-second read

$BBIOBullishLow
01

Why it matters

This is primarily a sentiment and positioning update for BBIO rather than a new fundamental disclosure. The main tradable element is the PT change and how it may influence near-term expectations relative to other recent targets.

02

Market read

Traders may monitor whether this PT move triggers additional revisions across the Street, but the article itself contains no new company-specific operational or clinical data.

03

What to watch

The article does not state the thesis behind the PT increase, so traders may discount it if it is not tied to a near-term catalyst.

Relevance 4/10Novelty 4/10Timing: as-of the analyst note publication date, for positioning around ongoing PT/rating revisions

Background

The piece summarizes an analyst action from Morgan Stanley on BridgeBio Pharma, including the updated price target and implied upside versus a recent close.

Company-level read

Ticker impact

$BBIOBullishMedium confidence
Context

Morgan Stanley maintained BridgeBio Pharma at Overweight and raised its price target to $91 from $88, implying a higher upside versus the Nov 12 close.

Expected impact

Likely modest upward bias as traders price in the higher target, with follow-through depending on whether other analysts adjust.

Evidence & confidence

The article provides a specific PT change and rating maintenance, but no new clinical, regulatory, or financial datapoint from BridgeBio itself.

Market effects

Limited spillover to biotech broadly; this is a single-name analyst target change.

No direct regional market linkage indicated.

No global macro or cross-market catalyst described.

Counterpoint

Analyst price-target hikes can lag or fail to translate into sustained price moves if the underlying catalysts (trial/regulatory milestones) are unchanged.

Key entities

  • BridgeBio Pharma

    Subject of the analyst action, with Morgan Stanley maintaining Overweight and raising the price target to $91.

  • Morgan Stanley

    Issued the rating maintenance and price-target increase referenced in the article.

Related articles

$LLYMed

Global Gene Therapy for Hearing Loss Market Report 2026 | Capture Growth to $1.71B by 2030 as Regeneron, Lilly, Sensorion and Astellas Advance AAV, CRISPR and Cochlear Delivery

The global gene therapy for hearing loss market is projected to reach $1.71B by 2030, with companies like Regeneron, Lilly, Sensorion, and Astellas focusing on AAV and CRISPR therapies. Regeneron's Otarmeni received FDA approval in 2026, and acquisitions, such as Regeneron's $109M purchase of Decibel Therapeutics, are shaping the market. North America leads, but Asia-Pacific is expected to grow rapidly.

$INOHighAI 9/10

KXCO's FDA ontology ranked INO-3107 first. After the approval, Inovio (INO) traded over 300% higher after hours. Three more FDA decisions are on our radar.

Inovio Pharmaceuticals (INO) received FDA approval for its drug VOCERYQ (INO-3107), leading to a 351.7% after-hours trading surge and a 215.0% gain in the next session. KXCO's AI ontology predicted this outcome. Three other FDA decisions are upcoming for BridgeBio (BBIO), Cogent (COGT), and Praxis (PRAX).

$BBIOMed

BridgeBio Pharma Earnings Call Signals Multi-Drug Breakout

BridgeBio Pharma (BBIO) reported Q3 earnings with $353.2M revenue, up from $120.7M YoY, driven by Attruby sales. The company highlighted three potential drug launches within seven months and a $1.5B cash position. Management expects continued revenue growth and narrowing losses, with Attruby on track to meet or exceed $4B peak sales.

$BBIOMedAI 8/10

BridgeBio (BBIO) Q3 2026 Earnings Call Transcript

BridgeBio (BBIO) reported Q3 2026 earnings, with Attruby's U.S. net product revenue at $253.2 million, up 14% quarter-on-quarter and 134% year-over-year. The company expects Attruby to meet or exceed $4 billion in peak year sales and sees similar potential in three other brands. Management highlighted strong performance among cardiologists and plans to target a broader range of prescribers. Positive real-world evidence and kidney protective signals were also discussed.

$BBIOMed

BridgeBio Pharma Inc (BBIO) (Q3 2026) Earnings Call Highlights: Attruby Surge Drives Record

BridgeBio Pharma (BBIO) reported a $31M sequential increase in Attruby revenue, with executives forecasting continued growth. The company expects $25M-$30M in near-term revenue and $1.5B cash to cover operational needs. Attruby's market share is driven by real-world evidence and renal protective data. The company anticipates an average operating loss of $90M-$100M per quarter in 2026, improving from 2025.